Last reviewed · How we verify
Magnesium sulfate administration
Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility.
Magnesium sulfate acts as a physiological calcium antagonist and NMDA receptor antagonist, reducing neuronal excitability and vascular smooth muscle contractility. Used for Seizure prophylaxis in preeclampsia and eclampsia, Acute myocardial infarction (arrhythmia management), Severe asthma exacerbation.
At a glance
| Generic name | Magnesium sulfate administration |
|---|---|
| Sponsor | University of California, San Francisco |
| Drug class | Electrolyte/mineral supplement; anticonvulsant |
| Target | NMDA receptor; L-type calcium channel |
| Modality | Small molecule |
| Therapeutic area | Obstetrics; Neurology; Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Magnesium sulfate blocks calcium influx into cells and antagonizes N-methyl-D-aspartate (NMDA) receptors, leading to decreased neuronal excitability and reduced smooth muscle contraction. This mechanism underlies its use in preventing seizures in eclampsia/preeclampsia and in acute migraine management. It also has vasodilatory properties and can reduce neuromuscular transmission.
Approved indications
- Seizure prophylaxis in preeclampsia and eclampsia
- Acute migraine headache
- Hypomagnesemia
- Cardiac arrhythmias (torsades de pointes)
Common side effects
- Flushing
- Sweating
- Hypotension
- Depressed reflexes
- Muscle weakness
- Respiratory depression
- Hypermagnesemia (with overdose)
Key clinical trials
- Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease (PHASE2)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Biomarkers in Management of Post Partum Preeclampsia (PHASE4)
- Comparison of Mean Duration of Analgesia Following the Administration of Bupivacaine With and Without Magnesium Sulphate in Ultrasound Guided Erector Spinae Plane Block in Modified Radical Mastectomy Patients (NA)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Magnesium vs. Dexmedetomidine in TURBT Under Spinal Anesthesia (NA)
- Adding Magnesium Sulphate to Combined Pectointercostal Plane and Erector Spinae Plane Blocks for Acute and Chronic Post-Mastectomy Pain (NA)
- Magnesium Sulfate Infusion on Postoperative Pain in Lumbar Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: